EORTC CLTF 2021 | Methods to access the clinical efficacy of mogamulizumab
Samuel Wilding
• 6 Oct 2021
Samuel Wilding, University of Manchester, Manchester, UK, explains the methods used to assess response to mogamulizumab in a Phase II study (NCT04745234) of mogamulizumab for cutaneous T-cell lymphoma (CTCL). Dermatological response was measured both prior to treatment and at peak response using the Modified Severity-Weighted Assessment Tool (mSWAT), which is obtained by multiplying the sum of body surface area affected by disease by a weighting factor for the severity of the disease. The hematological response was assessed using flow cytometry with markers for CD4, CD8, CD7 and CD26 to detect and quantify abnormal T-cells in peripheral blood. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
